Skip to content

Thoracic Paravertebral Block for Postoperative Pain Management After VATS

Thoracic Paravertebral Block for Postoperative Pain Management in PACU After VATS Surgeries: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06689358
Enrollment
81
Registered
2024-11-14
Start date
2022-11-01
Completion date
2024-08-01
Last updated
2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Opioids, Pain Management,, Thoracic Paravertebral Block. VATS, Regional Anesthesia

Brief summary

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS).

Detailed description

This randomized controlled trial evaluated the efficacy of a thoracic paravertebral block (TPVB) in reducing opioid requirements and pain intensity in the PACU after video-assisted thoracoscopic surgery (VATS). Adult patients scheduled for elective VATS who meet the eligibility criteria will be randomized to either Arm: Arm 1: General anesthesia with TPVB; Arm 2: General anesthesia alone (control group). Primary Outcome: to assess Opioid requirement in the PACU

Interventions

DRUG0.4 ml/kg of 0.5% bupivacaine

0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space

Sponsors

King Hussein Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Arm 1: General anesthesia with TPVB; Type: Experimental Intervention: 0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space. Arm 2: General anesthesia alone (control group). Type: No intervention (control) Intervention: No intervention

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients scheduled for elective VATS, ASA physical status II-III, BMI 19-40.

Exclusion criteria

* Patient refusal, coagulation disorders, contraindications to TPVB, chronic analgesic use, mental illness

Design outcomes

Primary

MeasureTime frameDescription
Opioid requirement in the PACUOpioid requirement assessed at 5 minutes, 15 minutes, 30 minutes post-PACU admission, and at PACU discharge (up to 4 hours)Opioid requirement in the PACU, recorded as yes or no.

Secondary

MeasureTime frameDescription
Pain intensity measured by Numeric Rating Scale -NRSPain intensity measured using the Numeric Rating Scale (NRS) at 5 minutes, 15 minutes, 30 minutes post-PACU admission, and at PACU discharge (up to 4 hours)Pain intensity measured by Numeric Rating Scale- NRS at several time points, Range: 0 (no pain) to 10 (worst imaginable pain), Interpretation: Higher scores indicate worse pain intensity

Countries

Jordan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026